back to cluster viewer
cluster path 1110100010001
110 words, 23,910 tokens
freq alpha suffix
Words in frequency order
1 | according | 23,762
|
2 | agents/circumstances | 19
|
3 | unbeknownst | 7
|
4 | 2.- | 3
|
5 | reponses | 3
|
6 | slt1 | 3
|
7 | -11.79 | 2
|
8 | -8.27 | 2
|
9 | -8.63 | 2
|
10 | ci=0.60 | 2
|
11 | ci=0.85 | 2
|
12 | ciated | 2
|
13 | fifteen- | 2
|
14 | monosensitised | 2
|
15 | respectively.compared | 2
|
16 | 'ability | 1
|
17 | 'began | 1
|
18 | 'opportunity | 1
|
19 | 'strategies | 1
|
20 | -1854 | 1
|
21 | -1·22 | 1
|
22 | -21.42 | 1
|
23 | -2·97 | 1
|
24 | -4·09 | 1
|
25 | 1/2-hourly | 1
|
26 | 13237327 | 1
|
27 | 17-sep‑2007 | 1
|
28 | 17.5/year | 1
|
29 | 18.9/year | 1
|
30 | 23592407 | 1
|
31 | 25861500 | 1
|
32 | 3concerning | 1
|
33 | 44,984 | 1
|
34 | 4:4:4:3 | 1
|
35 | 5+/-0.1 | 1
|
36 | 51+/-0.12 | 1
|
37 | 9·95 | 1
|
38 | acoording | 1
|
39 | acording | 1
|
40 | acorrding | 1
|
41 | alliesthesia | 1
|
42 | altruism-according | 1
|
43 | antistine-privine | 1
|
44 | applicabilities | 1
|
45 | asccording | 1
|
46 | b-muticentertrials | 1
|
47 | b-similar | 1
|
48 | br.26 | 1
|
49 | c3-adherent | 1
|
50 | caf-tgfbr2 | 1
|
51 | clusters-and | 1
|
52 | concommitent | 1
|
53 | conpared | 1
|
54 | crossresistance | 1
|
55 | data-linkage | 1
|
56 | dce-tool | 1
|
57 | difficul | 1
|
58 | disorder/reactions | 1
|
59 | eighteen- | 1
|
60 | evolutionist | 1
|
61 | exacerbation.. | 1
|
62 | extra-medically | 1
|
63 | extrabuccally | 1
|
64 | fo-supplementation | 1
|
65 | fpls | 1
|
66 | from1999 | 1
|
67 | h2-transfer | 1
|
68 | hamifera | 1
|
69 | htg1 | 1
|
70 | hydroiodides | 1
|
71 | in-addition | 1
|
72 | in15 | 1
|
73 | leucocyte-depletion | 1
|
74 | message/exposure | 1
|
75 | microfluid | 1
|
76 | mvpa-fmri | 1
|
77 | nct000351806 | 1
|
78 | nmb-saporin | 1
|
79 | noninferiorly | 1
|
80 | objectivel | 1
|
81 | outcomes-time | 1
|
82 | pbiq-r. | 1
|
83 | phage-display | 1
|
84 | pound149 | 1
|
85 | pound2020 | 1
|
86 | pre-suturing | 1
|
87 | purpose- | 1
|
88 | purpose/ | 1
|
89 | q3=152.7 | 1
|
90 | q3=5.28 | 1
|
91 | ranged277 | 1
|
92 | rd® | 1
|
93 | re-laparotomies | 1
|
94 | repeated-exposure | 1
|
95 | rhinometrically | 1
|
96 | rrrr/s | 1
|
97 | saiko | 1
|
98 | salmeterol.compared | 1
|
99 | selection/inability | 1
|
100 | semirandomly | 1
|
101 | skc-2014a | 1
|
102 | ske-2014a | 1
|
103 | smugglers | 1
|
104 | superior/comparable | 1
|
105 | suseptibile | 1
|
106 | thirteen- | 1
|
107 | uniaristata | 1
|
108 | ßblockers | 1
|
109 | β1-response | 1
|
110 | €808 | 1
|
Words in alphabetical order
1 | 'ability | 1
|
2 | 'began | 1
|
3 | 'opportunity | 1
|
4 | 'strategies | 1
|
5 | -11.79 | 2
|
6 | -1854 | 1
|
7 | -1·22 | 1
|
8 | -21.42 | 1
|
9 | -2·97 | 1
|
10 | -4·09 | 1
|
11 | -8.27 | 2
|
12 | -8.63 | 2
|
13 | 1/2-hourly | 1
|
14 | 13237327 | 1
|
15 | 17-sep‑2007 | 1
|
16 | 17.5/year | 1
|
17 | 18.9/year | 1
|
18 | 2.- | 3
|
19 | 23592407 | 1
|
20 | 25861500 | 1
|
21 | 3concerning | 1
|
22 | 44,984 | 1
|
23 | 4:4:4:3 | 1
|
24 | 5+/-0.1 | 1
|
25 | 51+/-0.12 | 1
|
26 | 9·95 | 1
|
27 | according | 23,762
|
28 | acoording | 1
|
29 | acording | 1
|
30 | acorrding | 1
|
31 | agents/circumstances | 19
|
32 | alliesthesia | 1
|
33 | altruism-according | 1
|
34 | antistine-privine | 1
|
35 | applicabilities | 1
|
36 | asccording | 1
|
37 | b-muticentertrials | 1
|
38 | b-similar | 1
|
39 | br.26 | 1
|
40 | c3-adherent | 1
|
41 | caf-tgfbr2 | 1
|
42 | ci=0.60 | 2
|
43 | ci=0.85 | 2
|
44 | ciated | 2
|
45 | clusters-and | 1
|
46 | concommitent | 1
|
47 | conpared | 1
|
48 | crossresistance | 1
|
49 | data-linkage | 1
|
50 | dce-tool | 1
|
51 | difficul | 1
|
52 | disorder/reactions | 1
|
53 | eighteen- | 1
|
54 | evolutionist | 1
|
55 | exacerbation.. | 1
|
56 | extra-medically | 1
|
57 | extrabuccally | 1
|
58 | fifteen- | 2
|
59 | fo-supplementation | 1
|
60 | fpls | 1
|
61 | from1999 | 1
|
62 | h2-transfer | 1
|
63 | hamifera | 1
|
64 | htg1 | 1
|
65 | hydroiodides | 1
|
66 | in-addition | 1
|
67 | in15 | 1
|
68 | leucocyte-depletion | 1
|
69 | message/exposure | 1
|
70 | microfluid | 1
|
71 | monosensitised | 2
|
72 | mvpa-fmri | 1
|
73 | nct000351806 | 1
|
74 | nmb-saporin | 1
|
75 | noninferiorly | 1
|
76 | objectivel | 1
|
77 | outcomes-time | 1
|
78 | pbiq-r. | 1
|
79 | phage-display | 1
|
80 | pound149 | 1
|
81 | pound2020 | 1
|
82 | pre-suturing | 1
|
83 | purpose- | 1
|
84 | purpose/ | 1
|
85 | q3=152.7 | 1
|
86 | q3=5.28 | 1
|
87 | ranged277 | 1
|
88 | rd® | 1
|
89 | re-laparotomies | 1
|
90 | repeated-exposure | 1
|
91 | reponses | 3
|
92 | respectively.compared | 2
|
93 | rhinometrically | 1
|
94 | rrrr/s | 1
|
95 | saiko | 1
|
96 | salmeterol.compared | 1
|
97 | selection/inability | 1
|
98 | semirandomly | 1
|
99 | skc-2014a | 1
|
100 | ske-2014a | 1
|
101 | slt1 | 3
|
102 | smugglers | 1
|
103 | superior/comparable | 1
|
104 | suseptibile | 1
|
105 | thirteen- | 1
|
106 | unbeknownst | 7
|
107 | uniaristata | 1
|
108 | ßblockers | 1
|
109 | β1-response | 1
|
110 | €808 | 1
|
Words in suffix order
1 | 2.- | 3
|
2 | purpose- | 1
|
3 | fifteen- | 2
|
4 | eighteen- | 1
|
5 | thirteen- | 1
|
6 | exacerbation.. | 1
|
7 | pbiq-r. | 1
|
8 | purpose/ | 1
|
9 | 25861500 | 1
|
10 | pound2020 | 1
|
11 | ci=0.60 | 2
|
12 | 5+/-0.1 | 1
|
13 | htg1 | 1
|
14 | slt1 | 3
|
15 | 51+/-0.12 | 1
|
16 | -1·22 | 1
|
17 | -21.42 | 1
|
18 | caf-tgfbr2 | 1
|
19 | -8.63 | 2
|
20 | 4:4:4:3 | 1
|
21 | -1854 | 1
|
22 | 44,984 | 1
|
23 | in15 | 1
|
24 | ci=0.85 | 2
|
25 | 9·95 | 1
|
26 | nct000351806 | 1
|
27 | br.26 | 1
|
28 | q3=152.7 | 1
|
29 | 17-sep‑2007 | 1
|
30 | 23592407 | 1
|
31 | -8.27 | 2
|
32 | 13237327 | 1
|
33 | ranged277 | 1
|
34 | -2·97 | 1
|
35 | €808 | 1
|
36 | q3=5.28 | 1
|
37 | -4·09 | 1
|
38 | pound149 | 1
|
39 | -11.79 | 2
|
40 | from1999 | 1
|
41 | skc-2014a | 1
|
42 | ske-2014a | 1
|
43 | alliesthesia | 1
|
44 | hamifera | 1
|
45 | uniaristata | 1
|
46 | salmeterol.compared | 1
|
47 | respectively.compared | 2
|
48 | conpared | 1
|
49 | monosensitised | 2
|
50 | ciated | 2
|
51 | microfluid | 1
|
52 | clusters-and | 1
|
53 | crossresistance | 1
|
54 | data-linkage | 1
|
55 | superior/comparable | 1
|
56 | suseptibile | 1
|
57 | outcomes-time | 1
|
58 | antistine-privine | 1
|
59 | repeated-exposure | 1
|
60 | message/exposure | 1
|
61 | β1-response | 1
|
62 | acording | 1
|
63 | according | 23,762
|
64 | altruism-according | 1
|
65 | asccording | 1
|
66 | acoording | 1
|
67 | acorrding | 1
|
68 | 3concerning | 1
|
69 | pre-suturing | 1
|
70 | mvpa-fmri | 1
|
71 | objectivel | 1
|
72 | dce-tool | 1
|
73 | difficul | 1
|
74 | 'began | 1
|
75 | nmb-saporin | 1
|
76 | fo-supplementation | 1
|
77 | leucocyte-depletion | 1
|
78 | in-addition | 1
|
79 | saiko | 1
|
80 | 17.5/year | 1
|
81 | 18.9/year | 1
|
82 | b-similar | 1
|
83 | h2-transfer | 1
|
84 | rrrr/s | 1
|
85 | agents/circumstances | 19
|
86 | hydroiodides | 1
|
87 | 'strategies | 1
|
88 | re-laparotomies | 1
|
89 | applicabilities | 1
|
90 | reponses | 3
|
91 | b-muticentertrials | 1
|
92 | fpls | 1
|
93 | disorder/reactions | 1
|
94 | ßblockers | 1
|
95 | smugglers | 1
|
96 | c3-adherent | 1
|
97 | concommitent | 1
|
98 | evolutionist | 1
|
99 | unbeknownst | 7
|
100 | phage-display | 1
|
101 | extrabuccally | 1
|
102 | extra-medically | 1
|
103 | rhinometrically | 1
|
104 | semirandomly | 1
|
105 | noninferiorly | 1
|
106 | 1/2-hourly | 1
|
107 | 'ability | 1
|
108 | selection/inability | 1
|
109 | 'opportunity | 1
|
110 | rd® | 1
|